Cancer immunotherapy efficacy is driven by tumour biology, not by its histology. Impact on drug development and approvals

2022 ◽  
Vol 162 ◽  
pp. 130-132
Author(s):  
Mélodie Bonvalet ◽  
François-Xavier Danlos ◽  
Stéphane Champiat ◽  
Mathieu Rouanne ◽  
Aurélien Marabelle
Keyword(s):  
Drug Development ◽  
Cancer Immunotherapy ◽  
Tumour Biology

scholarly journals A universal CAR-NK cell approach for HIV eradication

2021 ◽  
Vol 5 (3) ◽  
pp. 192-194
Author(s):  
Arosh S. Perera Molligoda Arachchige ◽  
Keyword(s):  
Drug Development ◽  
Hiv Infection ◽  
Nk Cells ◽  
Cancer Immunotherapy ◽  
Nk Cell ◽  
Therapeutic Drug ◽  
Effective Solution ◽  
Hiv Eradication ◽  
Novel Approaches ◽  
The Way

<abstract> <p>No therapeutic drug has been able to completely eradicate HIV-infection so far, even after decades of research. A major challenge in HIV drug development is its immense diversity. NK cells are well-known for their anti-viral and anti-tumor functions. Since recently, NK cells have gained interest of researchers as they have paved the way for novel approaches in controlling HIV-infection supported by promising results observed in cancer immunotherapy trials. Here we report an anti-DNP CAR-NK cell approach introduced by Lim et al. capable of recognizing 2,4-dinitrophenyl tagged to anti-gp160 antibodies, which seemingly provides an effective solution to counteract HIV variability.</p> </abstract>

scholarly journals Cancer immunotherapy trials: leading a paradigm shift in drug development

2016 ◽  
Vol 4 (1) ◽  
Author(s):  
Leisha A. Emens ◽  
Lisa H. Butterfield ◽  
F. Stephen Hodi ◽  
Francesco M. Marincola ◽  
Howard L. Kaufman
Keyword(s):  
Drug Development ◽  
Cancer Immunotherapy ◽  
Paradigm Shift

Abstract 519: EVOEXS21546 is a novel non-brain penetrant A2AR inhibitor for cancer immunotherapy with accelerated drug development

2019 ◽  
Author(s):  
Pierre Fons ◽  
Andy Bell ◽  
Michael Esquerre ◽  
Stephanie Versluys ◽  
Florie Bertrand ◽  
...  
Keyword(s):  
Drug Development ◽  
Cancer Immunotherapy

Abstract 519: EVOEXS21546 is a novel non-brain penetrant A2AR inhibitor for cancer immunotherapy with accelerated drug development

2019 ◽  
Author(s):  
Pierre Fons ◽  
Andy Bell ◽  
Michael Esquerre ◽  
Stephanie Versluys ◽  
Florie Bertrand ◽  
...  
Keyword(s):  
Drug Development ◽  
Cancer Immunotherapy

A relationship-based approach to improving the clinical trial experience.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14055-e14055
Author(s):  
Sarah MacKay Helou ◽  
Camber W. Gadberry ◽  
Nicholas Zahara ◽  
Claire Nickols ◽  
Tanya Vidhyarkorn ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Drug Development ◽  
Cancer Immunotherapy ◽  
Treatment Options ◽  
White Paper ◽  
Efficient Manner ◽  
Trial Experience ◽  
New Treatment ◽  
Early Phase Clinical Trials ◽  
New Treatments

e14055 Background: The rapidly evolving field of Cancer Immunotherapy (CIT) has mobilized biopharma to develop promising new treatments while at the same time created a need to expedite the pathway of those new therapies from bench to bedside. This race to bring innovative treatments to patients has engendered heightened levels of competition for the attention of and partnership with the best research institutions in the biopharma industry. Methods: Recognizing this reality, Roche created the immunotherapy Centers of Research Excellence (imCORE) Network: a network of leading cancer immunotherapy centers worldwide. The vision of this network was to partner with sites to streamline the operational delivery of the Roche Genentech portfolio while deepening the collective understanding of the science to prioritize and accelerate the most promising new treatment options for our patients. Creation of a network was not a novel idea, but Roche set out to build a network unique to the biopharma industry – one which was relationship-based where the site/sponsor relationship serves as the foundation for driving both collaborative scientific investigations and operational efficiencies in support of Roche’s clinical trials. While the identification and optimization of promising candidate drugs in the preclinical and translational settings are critical first steps in the drug development process, the initiation and operationalization of early phase clinical trials are equally important in the multidimensional cycle of drug development. Results: See Conclusions. Conclusions: This white paper will provide an overview of imCORE’s origins with a focus on the strategic importance of the site-sponsor relationship and the mutual value that is derived from the combined benefits of these relationships and in conducting early clinical trials more efficiently across Roche’s CIT portfolio. Further examination of communication and operational improvement to support the network will be highlighted as key drivers in creating and sustaining meaningful site/sponsor relationships that better facilitate the operationalization of clinical trials and ultimately brings novel therapies to patients in a more efficient manner than in the past.

Sign in / Sign up

Export Citation Format

Share Document